Visceral Hypersensitivity: Why IBS Hurts When Tests Come Back Normal

Visceral hypersensitivity is a neurobiological state in which the nerves of the gut and the brain regions that process gut signals have become pathologically sensitive. Normal digestive events — gas, stretching, contractions — are experienced as painful because the signalling system has been amplified. The tissue is not damaged; the signalling about the tissue is. It is the core mechanism of IBS under the Rome IV framework, and it responds measurably to gut-directed hypnotherapy, CBT-for-IBS, and low-dose tricyclic antidepressants.

Visceral hypersensitivity is the clinical term for a state in which the nerves carrying sensation from the internal organs — particularly the gut — fire pain or discomfort signals at stimuli that would not ordinarily produce pain. The word “visceral” refers to the viscera, the internal organs of the chest and abdomen. The word “hypersensitivity” means the sensitivity is elevated above the normal range.

It is important to distinguish visceral hypersensitivity from normal sensitivity and from a lowered pain threshold in a general sense. A normal gut has its own baseline sensitivity — you can feel a very full stomach, you can feel an urgent need to have a bowel movement, you can feel sharp pain in the context of true injury or infection. That is healthy interoception working as designed. Visceral hypersensitivity is the condition in which signals that would normally stay below conscious awareness — routine gas movement, normal peristalsis, mild distension after a meal, the large intestine's natural contraction patterns — cross the threshold into conscious sensation and are often experienced as uncomfortable or painful.

Two ways to frame it that patients find clarifying:

• The gain-dial framing: imagine your gut nerves as a microphone and your brain as the sound system. In a healthy system, the gain is set so that only meaningful signals get amplified. In visceral hypersensitivity, the gain has been cranked up, so background noise (normal digestion) is broadcast at a volume that feels like alarm.
• The threshold framing: every sensation has a threshold below which it does not register consciously. Visceral hypersensitivity lowers that threshold, so sensations that used to stay below awareness now routinely cross it.

Crucially, visceral hypersensitivity is not an interpretation problem or a tendency to catastrophise — it is a measurable change in the biology of the nervous system. Controlled rectal distension studies have reproducibly shown that IBS patients experience pain at lower distension volumes than healthy controls, irrespective of what the patient thinks or expects. The sensitivity is calibrated into the nervous system, not added by the mind on top of normal signals.

Visceral hypersensitivity is not one thing — it is a final common pathway fed by two distinct mechanisms that can occur separately or, more commonly, together. Understanding which is dominant for a given person helps explain why different treatments produce different effects.

Most IBS patients have both. Chronic peripheral input tends to drive secondary central sensitization over time, which is why IBS that was initially post-infectious often develops stronger central features the longer it persists. The nervous system learns.

The clinical implications of the distinction are substantial:

• Peripheral-dominant presentations often respond well to peripherally-targeted interventions: low-FODMAP dietary change, rifaximin where SIBO is present, treatment of underlying inflammation, probiotics, gut-targeted antispasmodics.
• Central-dominant presentations respond better to centrally-targeted interventions: gut-directed hypnotherapy, CBT for IBS, mindfulness-based approaches, low-dose tricyclic antidepressants acting at spinal and central pain pathways.
• Mixed presentations — the majority — tend to do best with combined approaches that address both layers. Peters 2016 (PMID 27397586), which directly compared gut-directed hypnotherapy (central) to the low-FODMAP diet (peripheral), found both effective, with the two working through different pathways.

Mayer and colleagues have published extensively on the brain-imaging correlates of central sensitization in IBS — fMRI studies consistently find altered activation in the insula, anterior cingulate cortex, and amygdala during rectal distension, showing that the same physical input is being processed by a demonstrably different central system.

The gold standard for measuring visceral hypersensitivity in research is the rectal barostat balloon test. A small, thin-walled balloon is placed in the rectum and connected to a computer-controlled pump that inflates it at precise, reproducible volumes and pressures. The patient reports when they first feel the balloon, when the sensation becomes uncomfortable, and when it becomes painful. The volumes at which these thresholds occur are recorded.

Dozens of studies over three decades have used this methodology. The findings are consistent: IBS patients report pain at lower distension volumes than healthy controls. Rectal hypersensitivity is one of the most reliably reproduced biological findings in IBS research, and is a core part of why Rome IV retired older “functional disorder” framing in favour of “disorders of gut-brain interaction.”

In ordinary clinical practice outside of research centres, rectal barostat testing is rarely performed. It is labour-intensive, requires specialised equipment, and does not usually change treatment decisions in ways that justify routine use. Instead, visceral hypersensitivity is inferred from the overall clinical picture:

• A Rome IV symptom pattern (recurrent abdominal pain with defecation-related features)
• Pain and discomfort out of proportion to normal digestive events
• Normal structural testing on endoscopy, imaging, and labs
• A history consistent with sensitization (post-infectious onset, chronic stress, early-life adversity, strong family history, onset during perimenopause)
• Daily symptom diaries showing the pattern and triggers
• Response patterns to initial treatments (central vs peripheral response often helps clarify which mechanism dominates)

Functional MRI (fMRI) studies have added a second layer of measurement — not just the behavioural threshold but the brain activation patterns that accompany visceral stimulation. Mayer and colleagues have shown reproducible differences in the insula, anterior cingulate cortex, and amygdala between IBS patients and controls during rectal distension, providing neurobiological corroboration of what the barostat test measures behaviourally.

The practical takeaway: you do not need a barostat test to have visceral hypersensitivity diagnosed and treated. A careful clinical history and a Rome IV-confirmed IBS diagnosis after alarm features have been ruled out are what most patients will encounter. The research apparatus exists to validate the mechanism; the clinical apparatus exists to treat it.

This is the question that lands most people on this page. You have had every reasonable test. The gastroenterologist says everything looks fine. And yet you have pain most days. How is this possible?

The short answer: the conventional diagnostic toolkit measures structure. Visceral hypersensitivity is a problem of signalling. These are fundamentally different things.

Consider what each test is actually designed to find:

• Colonoscopy and endoscopy look for visible tissue damage — ulcers, inflammation, polyps, tumours, structural narrowing, abnormal blood vessels. They measure how the gut looks.
• CT scans, ultrasound, and MRI look for larger structural problems — obstructions, masses, wall thickening, fluid collections. They measure the three-dimensional architecture of the abdomen.
• Standard blood work looks for inflammation markers (CRP, ESR, faecal calprotectin), infection, anaemia, and organ dysfunction. It measures what is circulating in blood and what is leaking into the gut lumen.
• Stool studies look for infection (ova, parasites, bacteria, viruses), blood, and inflammatory markers. They measure what is leaving the gut.

None of those tests measure the gain of the nervous system. None of them measure how loudly the sensory neurons in the gut wall fire in response to normal distension. None of them measure how pain-processing regions of the brain interpret the signals that arrive from the gut. None of them measure vagal tone, HPA-axis reactivity, or the activity of the enteric nervous system. All of those things can be profoundly dysregulated in a gut that is structurally normal.

This is not a failure of medicine. Those tests are essential — their job is to rule out structural disease that requires very different treatment (inflammatory bowel disease, cancer, celiac, microscopic colitis, severe motility disorders). If your tests are normal, that is a genuinely reassuring finding in the sense that it rules out those serious structural conditions. What it does not do is address what is happening — because visceral hypersensitivity cannot be diagnosed on an imaging report.

Rome IV specifically reframed IBS and the related functional GI disorders as “disorders of gut-brain interaction” precisely to make this point clearer. The older “functional” language sometimes carried a pejorative undertone — “functional” treated as meaning “not real” or “all in your head.” The current framing names the gut-brain axis directly as the organising mechanism and puts dysregulated signalling at the centre of the diagnostic category.

So when a clinician says “the tests are normal, it is just IBS,” the “just” is a communication failure. There is nothing “just” about a measurable dysregulation of the gut-brain axis that affects an estimated 10-15% of the adult population. Normal structural tests mean the structure is intact. They do not mean the problem is not real.

Visceral hypersensitivity does not arise from nothing. Research has identified a converging set of drivers that contribute to its development and maintenance. Most people with significant visceral hypersensitivity have two or three of these in their history, often layered on top of each other.

Post-infectious origin

One of the best-characterised triggers. A bacterial or viral gastroenteritis — Campylobacter, Salmonella, Shigella, norovirus, Giardia, and more recently COVID-19 — produces acute inflammation and acute immune activation in the gut. In a subset of patients (systematic reviews report 6-17%), the acute infection resolves but leaves behind persistent low-grade inflammation, altered enteric nervous system signalling (including increased enterochromaffin cell density and altered serotonin handling), increased intestinal permeability, and a disrupted microbiome. The net result is a gut that looks normal on imaging but whose sensory nerves remain calibrated to the high-alarm state of the original infection. The inflammation resolves; the sensitization persists. This is post-infectious IBS, and it is a textbook case of inflammation seeding long-term peripheral and central sensitization.

Chronic stress and HPA-axis dysregulation

The hypothalamic-pituitary-adrenal (HPA) axis is the body's main stress-response system. Sustained activation — months or years of elevated baseline stress, not single acute events — has been shown to increase gut permeability, alter motility, shift the microbiome, and directly sensitise visceral pain pathways through corticotropin-releasing factor (CRF) signalling. CRF has receptors in the gut itself and directly modulates visceral sensitivity and motility. Chronic stress is a sustained physiological load on the gut-brain axis, not just a psychological state.

Early-life adversity and ACEs

Adverse childhood experiences (ACEs) — chronic stress, trauma, neglect, household dysfunction in the developing years — appear to be a particularly strong background risk factor for visceral hypersensitivity in adulthood. Epidemiological research has consistently found higher ACE scores in IBS populations than in matched controls. The mechanism is thought to be developmental: the HPA axis and stress-response architecture calibrate during childhood, and early adversity sets a more reactive default state that persists into adulthood. The sensitised stress-response system is then more prone to driving visceral sensitization when later triggers (infection, acute stress, dietary change) appear. This is not a moral failing or a character flaw — it is a neurobiological setting that was calibrated by factors largely outside the person's control.

Microbiome dysbiosis

The gut microbiome has direct effects on visceral sensitivity. Bacterial metabolites influence enteric nerve activity, immune tone, and motility. Dysbiosis — reduced diversity, shifted ratios, overgrowth of pro-inflammatory species — has been repeatedly associated with IBS and measured visceral hypersensitivity. Small intestinal bacterial overgrowth (SIBO) is documented in a meaningful proportion of IBS patients and can drive peripheral sensitization directly.

Dietary and FODMAP-driven exacerbation

Fermentable oligo-, di-, mono-saccharides and polyols (FODMAPs) are short-chain carbohydrates that are poorly absorbed in the small intestine. In a healthy gut, they reach the large intestine where bacteria ferment them to gas and short-chain fatty acids — a normal physiological process that does not cause pain. In a sensitized gut, the same fermentation produces distension and gas that is interpreted as painful because the nervous system gain is elevated. FODMAPs do not cause visceral hypersensitivity per se — many people eat high-FODMAP diets without any symptoms — but they are one of the most common exacerbating loads on an already-sensitized system. This is why low-FODMAP dietary protocols reduce symptoms but do not reverse the underlying sensitization.

Hormonal influences

Estrogen and progesterone both modulate visceral pain thresholds and gut motility, which is why many women report predictable symptom flares around menstruation and during perimenopause. The cyclical interaction of these hormones across the menstrual cycle is one of the contributors to the roughly 2:1 female-to-male prevalence ratio of IBS globally. Hormonal variability does not itself cause visceral hypersensitivity but can reveal it, exacerbate it, and sometimes tip a previously compensated system into a symptomatic state — which is why new-onset IBS during perimenopause is a common clinical presentation.

Visceral hypersensitivity is not a feature of IBS — it is generally considered the core feature of IBS pathophysiology. Under the Rome IV framework (Drossman and colleagues, 2016), IBS is classified as a disorder of gut-brain interaction in which altered visceral perception is central to the symptom experience. The other commonly cited drivers of IBS — altered motility, microbiome dysbiosis, post-infectious inflammation, stress, genetic predisposition, hormonal influences, FODMAP sensitivity — operate largely by either contributing to the development of visceral hypersensitivity or by providing the triggering loads that a sensitized gut then responds to.

This is why two people with ostensibly the same diet, same stress level, and same microbial environment can have completely different symptom experiences. A healthy gut with normal visceral perception can process considerable fermentation, motility variation, and dietary variability without any of it crossing into conscious discomfort. A sensitized gut registers the same inputs as painful because the gain is turned up. The difference is not in what is happening in the gut lumen; it is in how the signalling system is calibrated.

This has direct treatment implications. Peripheral-only interventions (dietary restriction, probiotics, antibiotics for SIBO, antispasmodics) reduce the input, but if the underlying sensitivity remains, symptoms rebound once the restriction is relaxed. Central-acting interventions (gut-directed hypnotherapy, CBT-for-IBS, low-dose tricyclic antidepressants, mindfulness-based approaches) can produce more durable change because they act on the calibration rather than the load. Many people benefit most from combining both.

For a broader treatment of the IBS pathophysiology picture, see the sister pillar on what causes IBS — which walks through the nine evidence-based drivers in depth.

There are several interventions with real evidence for reducing visceral hypersensitivity. The most useful framing is by mechanism: central-acting (retraining how the brain processes visceral signals), peripheral-acting (reducing the input load from the gut), and combined.

Gut-directed hypnotherapy (central)

Gut-directed hypnotherapy is the intervention with the strongest evidence base specifically for reducing central visceral sensitization. Peter Whorwell's original 1984 Lancet paper kicked off four decades of research. The Manchester Protocol (Miller 2015, PMID 25736234) audited 1,000 consecutive adult IBS patients treated with a 12-session protocol and reported 76% response, with sustained benefit at 5-year follow-up in the majority of responders. Peters 2016 (PMID 27397586) directly compared gut-directed hypnotherapy to the low-FODMAP diet in a randomised design and found them equivalent on GI symptoms, with hypnotherapy superior on psychological outcomes. The mechanism appears to be primarily retraining of central processing — Whorwell's own research and subsequent work has shown that patients who respond to gut-directed hypnotherapy show measurably increased rectal distension thresholds (they tolerate larger volumes before pain registers) after completing the protocol. This practice follows the Manchester Protocol structure.

Cognitive behavioural therapy for IBS (central)

CBT adapted specifically for IBS targets the cognitive, attentional, and behavioural amplification of visceral sensations. It addresses the hypervigilance, catastrophising, and anticipatory anxiety patterns that can add a second layer of amplification on top of the underlying neurobiological sensitivity. Multiple RCTs and meta-analyses support its efficacy in IBS, with effect sizes comparable to gut-directed hypnotherapy. Some clients do better with the more active-problem-solving style of CBT; others do better with the experiential, state-change style of hypnotherapy. Both are evidence-based options.

Tricyclic antidepressants at low dose (central, spinal)

Tricyclic antidepressants (TCAs) such as amitriptyline, nortriptyline, and desipramine at low doses — typically 10-50 mg nightly, considerably below the antidepressant dose — have decades of evidence for visceral pain. At these doses the mechanism is primarily analgesic rather than mood-altering: the medication modulates descending pain pathways in the spinal cord and central nervous system, effectively turning down the gain on visceral pain processing. TCAs are a physician-prescribed intervention with real side effects (dry mouth, constipation, drowsiness, orthostatic effects) and require appropriate medical management. They are a standard part of the gastroenterology toolkit for refractory visceral pain.

Low-FODMAP dietary protocol (peripheral)

The Monash University low-FODMAP protocol reduces peripheral fermentable load, giving a sensitized gut less of the input it over-reacts to. It does not reverse the underlying sensitization — re-introduction of FODMAPs typically brings symptoms back — but it can meaningfully reduce day-to-day symptom burden and is useful both as a stand-alone intervention and as part of combined treatment. Best run with a registered dietitian experienced in the protocol, because the reintroduction phase is as important as the elimination phase. See low-FODMAP vs hypnotherapy for a deeper comparison.

Gut-brain axis interventions (autonomic / vagal)

Interventions that improve vagal tone and autonomic balance — slow breathing protocols, regular aerobic exercise, mindfulness-based stress reduction, yoga, sleep regularisation — tend to produce corresponding improvements in visceral sensitivity over time. The mechanism is not symptom distraction; it is genuine modulation of the autonomic nervous system context in which the gut-brain axis operates. Effect sizes are typically smaller than the targeted interventions above, but these practices compound with them well and are widely available.

Probiotics, specific (peripheral / microbiome)

Specific probiotic strains — most notably Bifidobacterium infantis 35624 — have evidence for reducing visceral pain and IBS symptoms in subsets of patients. The evidence for probiotics broadly is mixed because the field is strain-specific and many over-the-counter products have not been studied. Clinician guidance on strain selection matters. Probiotics are not a substitute for targeted visceral pain treatment but can be a useful adjunct, particularly where microbiome dysbiosis is suspected.

A common source of frustration for IBS patients is that the pain medications that reliably work for somatic pain — a twisted ankle, a muscle strain, a headache — tend to be minimally effective or even counterproductive for visceral pain. There are concrete biological reasons for this.

NSAIDs (ibuprofen, naproxen, aspirin)

NSAIDs work by blocking inflammatory mediators (prostaglandins) at the site of injury. They excel at inflammatory somatic pain — sprains, dental pain, muscle soreness, headache. Visceral hypersensitivity in IBS is generally not primarily inflammatory in the NSAID-responsive sense. There is a low-grade immune component in many cases, but the dominant mechanism is nervous-system gain rather than acute inflammation. Beyond minimal benefit, NSAIDs can actively worsen IBS by irritating the gastric and small intestinal lining, increasing permeability, and triggering or exacerbating dyspeptic symptoms. Routine NSAID use is generally not recommended in IBS.

Opioids (codeine, tramadol, stronger narcotics)

Opioids are actively contraindicated in IBS. Two mechanisms explain why. First, opioids dramatically slow gut motility — this is why opioid-induced constipation (OIC) is a near-universal side effect. In a gut that is already dysmotile, this can precipitate severe constipation, bloating, and pain. Second, chronic opioid use can produce narcotic bowel syndrome, in which the visceral pain paradoxically increases despite and because of the opioid, driving escalating dose requirements and worsening symptoms. Gastroenterology practice guidelines across multiple jurisdictions uniformly recommend against chronic opioid use for functional abdominal pain.

Acetaminophen / paracetamol

Acetaminophen is broadly safer than NSAIDs or opioids for this population, but its analgesic effect on visceral pain is modest. Many patients find it takes the edge off mild pain without addressing the underlying mechanism. Used occasionally for breakthrough pain, it is reasonable; relied on as a mainstay of visceral pain management, it is not sufficient.

What actually works on the pain pathway

The pharmacological tools that do work on visceral pain act centrally rather than peripherally: low-dose tricyclic antidepressants (acting at the spinal dorsal horn and descending pain pathways), serotonin-modulating agents in specific presentations, and in selected severe cases, gabapentinoids. All of these are physician-managed choices with specific indications and side-effect profiles. The non-pharmacological tools — gut-directed hypnotherapy, CBT-for-IBS, mindfulness — work on the same central pathways without the medication burden, which is part of why they are first-line or early-line options in many modern IBS algorithms. The common theme across everything that works is mechanism-matching: visceral hypersensitivity is a central-processing problem, and the treatments that help are the ones that act on central processing.

Gut-directed hypnotherapy is worth a section of its own because it is one of the better-evidenced and more mechanistically specific treatments for visceral hypersensitivity — and because patients frequently arrive with significant misconceptions about what it is and how it works.

Clinical hypnosis is a focused-attention state in which the nervous system becomes more receptive to targeted therapeutic input. It is not unconsciousness, not mind control, and not stage hypnosis. In gut-directed hypnotherapy, the clinician uses this focused state to deliver structured therapeutic suggestions specifically addressed to gut function: the gut settling into a regular, comfortable rhythm; sensations that have felt painful becoming quieter; the nervous system's alarm reactivity dialling down; the conscious mind stepping back from hypervigilant attention to the belly. The protocol is delivered over multiple sessions with home-practice audios that reinforce the work between sessions.

The measurable effects on visceral hypersensitivity have been reported in research over 40 years. Whorwell's 1984 Lancet paper opened the field. Miller 2015 (PMID 25736234, n=1,000), Peters 2016 (PMID 27397586), and numerous smaller trials have replicated the effect and extended it to objective measures: patients who respond to gut-directed hypnotherapy show increased rectal distension thresholds on barostat testing after the protocol — they tolerate more distension before reporting pain. Brain imaging work by Mayer and colleagues has added mechanistic detail, showing changed activation patterns in the insula, anterior cingulate cortex, and other pain-processing regions during visceral stimulation. This is measurable neurobiological change, not a psychological phenomenon in the colloquial sense.

Hypnotherapy is not a cure for visceral hypersensitivity — that language overstates the evidence. What it is is a durable, well-evidenced reduction in sensitization that produces lasting benefit in the majority of responders. Miller 2015's 5-year follow-up data is one of the more impressive long-term outcome datasets in the functional GI literature. For a deeper look at the clinical picture, see hypnotherapy for IBS.

Reversing visceral hypersensitivity takes time because it is a calibration of the nervous system rather than an acute process. Patients with a realistic timeline tend to notice earlier markers of progress and stay engaged long enough to see substantial change.

Based on the research and standard clinical experience:

• Week 1-2 (sessions 1-2): Early markers of change — often improved sleep, reduced baseline anxiety about gut symptoms, small reductions in pain intensity during lower-load days, better tolerance of smaller meals. Symptom diaries often show the first signs here, even before the patient consciously notices.
• Week 3-4 (sessions 3-4): Response typically becomes clearly visible. Miller 2015's data suggested that patients who were going to respond usually showed it by about session 4. Pain intensity, symptom frequency, and reactivity to triggers all often shift here. This is also a reasonable check-in point for reviewing whether the approach is working.
• Week 5-8 (sessions 5-8): Benefits consolidate and extend. Many responders notice wider tolerance of previously triggering foods, reduced anticipatory anxiety, and greater flexibility in daily activities. This is the period where the retraining really takes hold.
• Week 9-12 (sessions 9-12): Full protocol completion. In the Manchester Protocol, this is where the work ends for most clients, and where the 5-year durability data from Miller 2015 begins to apply.
• Beyond 12 weeks: For the majority of responders, sustained benefit without needing ongoing sessions. A small minority find occasional tune-up sessions helpful during stressful life periods (job changes, bereavement, significant illness). A small subset with complex or treatment-resistant presentations benefit from an extended protocol.

For dietary protocols, the timeline is different. Low-FODMAP elimination typically produces noticeable symptom reduction within 2-4 weeks, but the reintroduction phase (adding foods back in to identify individual triggers) takes another 6-8 weeks to complete properly. Tricyclic antidepressants at visceral-pain doses typically take 4-8 weeks to show meaningful pain benefit at a given dose.

The honest framing: visceral hypersensitivity that has been building for years or decades is not going to fully resolve in weeks. Meaningful reduction in 6-12 weeks is achievable and well-documented. Sustained improvement over months to years is the expected outcome for responders. Fast is relative, and the most reliable path to faster change is starting earlier and combining the right interventions for your specific driver pattern.

Most visceral hypersensitivity responds to the treatments outlined above. In a minority of cases, a structural or active driver is keeping the nervous system in a sensitized state, and no amount of central retraining will produce durable change until that driver is addressed. This is part of why a thorough physician-led workup is the non-negotiable starting point.

Specific situations where the underlying driver needs attention first (or alongside) central treatment:

• Active inflammatory bowel disease (Crohn's, ulcerative colitis): active inflammation drives ongoing peripheral sensitization. Central-only treatment will underperform until the inflammation is controlled. Gastroenterology-led medical treatment of the IBD is the priority.
• Active SIBO (small intestinal bacterial overgrowth): ongoing bacterial overgrowth drives fermentation, gas, and peripheral nerve irritation that can overwhelm central retraining. Treatment (often rifaximin, sometimes combined protocols) addresses the peripheral driver. Hypnotherapy and dietary work then have a better foundation to act on.
• Pelvic floor dysfunction: dyssynergic defecation and pelvic floor muscle dysfunction can drive persistent pain and incomplete evacuation that mimics or coexists with IBS. Pelvic floor physiotherapy (often using biofeedback) is the targeted treatment. Central approaches tend to plateau if significant pelvic floor dysfunction is present and unaddressed.
• Unresolved celiac disease or non-celiac gluten sensitivity: ongoing dietary exposure in someone with celiac drives ongoing gut inflammation. Serological screening and duodenal biopsy where indicated are the standard workup; strict gluten exclusion is the treatment.
• Endometriosis-associated visceral pain: endometriosis implants on or near the gut can drive pain that mimics IBS and does not fully respond to IBS-directed treatment. Gynaecology referral for suspected endometriosis is the pathway.
• Active, untreated trauma or severe mental health conditions: significant unprocessed trauma or severe, untreated depression or anxiety can sustain the stress-response architecture in a way that central-only IBS treatment cannot fully address. Trauma-focused therapy and mental health treatment running alongside, or sometimes before, gut-directed work tends to produce better outcomes.
• Ongoing heavy alcohol use, chronic sleep deprivation, or poorly-managed chronic illness: these sustain HPA-axis dysregulation and nervous-system gain. Addressing them is part of what makes downstream treatment effective.

A reasonable clinical framing: gut-directed hypnotherapy and related central-acting treatments work on the gain of the nervous system. If something is actively cranking the gain up faster than the treatment can turn it down, the treatment will underperform. The answer is not to abandon central treatment — it is to address the driver that is keeping the gain elevated, so the central work has something to build on.

This is also why a careful clinical intake matters. Timeline of onset, relationship to infections or life events, dietary and hormonal patterns, sleep, mental health, and relevant medical history all factor into working out what the dominant drivers are and what treatment sequence is likely to produce the best outcome.

If you have read this far, the key points are probably starting to cohere:

• Visceral hypersensitivity is a real, measurable neurobiological state — not an interpretation, exaggeration, or psychological tendency.
• It has two main layers (peripheral and central) that usually occur together, and it is the core mechanism of IBS under Rome IV.
• Normal structural tests come back normal because they measure structure, not signalling. The tests are doing their job correctly; visceral hypersensitivity is simply not what they measure.
• It is driven by a combination of post-infectious origin, chronic stress, early-life adversity, microbiome shifts, hormonal influences, and dietary load — usually two or three of these together.
• It responds to treatments that act on central processing (gut-directed hypnotherapy, CBT-for-IBS, low-dose tricyclic antidepressants) and to treatments that reduce peripheral load (low-FODMAP, targeted microbiome work). Combined approaches often do best.
• Ordinary pain medications do not target the mechanism and in the case of opioids can worsen it. Matching mechanism to treatment is what works.
• The realistic timeline for meaningful reduction is 6-12 weeks of treatment, with benefits often sustained at multi-year follow-up in responders.
• In a minority of cases, an underlying structural or active driver (IBD, SIBO, pelvic floor dysfunction, endometriosis, celiac, unresolved trauma) needs addressing first before central treatment can fully produce change.

The single most important reframe for most patients is this: your gut is not broken, your nervous system has become miscalibrated, and miscalibration can be retrained. That framing is not optimism; it is what forty years of visceral hypersensitivity research consistently shows. It does not mean the pain is less real — it means the pain is not permanent.

The starting point for any meaningful treatment path is a clear Rome IV diagnosis, a physician-led workup that has ruled out structural causes, and then a thoughtful treatment sequence matched to the dominant drivers in your specific case. Hypnotherapy is complementary care, not a substitute for medical diagnosis or treatment, and it is not a regulated health profession in Alberta. Used appropriately alongside medical care, it is one of the better-evidenced options for the central-sensitization component that is at the heart of most IBS.

Related reading: What causes IBS · The gut-brain connection · Hypnotherapy for IBS · IBS and anxiety · Low-FODMAP vs hypnotherapy